Analysts Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $44.10

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been given a consensus rating of “Moderate Buy” by the fourteen research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $44.10.

A number of research analysts have issued reports on OLMA shares. Citigroup upped their price objective on Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. The Goldman Sachs Group reduced their price target on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Jefferies Financial Group started coverage on shares of Olema Pharmaceuticals in a research note on Thursday, March 19th. They issued a “buy” rating and a $40.00 target price on the stock. Guggenheim reduced their target price on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Finally, Wolfe Research assumed coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They set a “peer perform” rating for the company.

Institutional Trading of Olema Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Siren L.L.C. bought a new stake in Olema Pharmaceuticals during the 4th quarter valued at $82,518,000. Janus Henderson Group PLC grew its position in shares of Olema Pharmaceuticals by 87.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock valued at $167,901,000 after purchasing an additional 3,124,345 shares in the last quarter. Cormorant Asset Management LP purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at $68,750,000. RA Capital Management L.P. bought a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at $65,000,000. Finally, Bain Capital Life Sciences Investors LLC raised its stake in shares of Olema Pharmaceuticals by 24.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after purchasing an additional 1,664,687 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Trading Down 3.0%

OLMA stock opened at $11.91 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The business has a fifty day moving average price of $12.17 and a 200 day moving average price of $18.07. Olema Pharmaceuticals has a fifty-two week low of $4.37 and a fifty-two week high of $36.26. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -5.90 and a beta of 2.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, hitting the consensus estimate of ($0.52). Analysts expect that Olema Pharmaceuticals will post -2.22 EPS for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.